Going Too Fast

A recent clinical trial for a cancer immunotherapy drug from the biotech company Incyte failed, surprising many observers. Since then, a new editorial in Science notes, three companies have canceled, suspended, or downsized 12 other phase III trials of the compound, epacadostat, or two similar drugs. The compounds were designed to block an enzyme called indoleamine (2,3)- dioxygenase (IDO), and therefore turn the immune system on cancer cells.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.